No Data
Hunan Fangsheng Pharmaceutical (603998.SH): Product renewal in the national medical insurance catalog (2024).
On November 28, 2023, Hunan Fangsheng Pharmaceutical (603998.SH) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources and Social Security issued the notice regarding the "Publication of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" [Medical Insurance Issue No. 33 (2024)] (hereinafter referred to as the "2024 Edition of the Medical Insurance Catalog"). According to this notice, the company's pediatric Jingxing cough granules and Xuanqi bone-strengthening tablets will be included in the "2024 Edition of the Medical Insurance Catalog" during the negotiation renewal period, and there are no withdrawals or additions for the company's other major products and those of its controlling subsidiaries this time.
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Stock Has Fared Decently: Is the Market Following Strong Financials?
Fangsheng Pharmaceutical: Fangsheng Pharmaceutical Report for the Third Quarter of 2024
Fangsheng Pharmaceutical Report for the Third Quarter of 2024
Fangsheng Pharmaceutical\'s business data announcement for the first three quarters of 2024
Investors Don't See Light At End Of Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Tunnel And Push Stock Down 29%
